Elacestrant for advanced or metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic breast cancer (cancer that has spread or cannot be fully removed) that is ER-positive and HER2-negative.
- You have a specific gene change called an ESR1 mutation, which the trial will test for.
- You are a woman who has gone through menopause.
- Your cancer has worsened while taking a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) combined with either fulvestrant or an aromatase inhibitor.
- You have not had certain prior treatments, including the study drug or other similar hormone therapies or antibody-drug conjugates.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.